Article Details

SRF388, a First-in-Class IL-27 Antibody, Demonstrates Monotherapy Activity in Data Presented at ...

Retrieved on: 2021-06-04 11:03:45

Tags for this article:

Click the tags to see associated articles and topics

SRF388, a First-in-Class IL-27 Antibody, Demonstrates Monotherapy Activity in Data Presented at .... View article details on hiswai:

Excerpt

About the SRF388-101 Clinical Trial: The trial is a Phase 1, open-label, multicenter, first-in-human dose-escalation trial of SRF388, a monoclonal ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up